BMC Cancer:晚期鼻咽癌治疗方案比较

2015-12-23 Seven L译 MedSci原创

研究者对经调强放疗(IMRT)治疗后的局部区域晚期鼻咽癌患者进行了一项研究,比较以下几种治疗方式的生存结局和急性毒性作用:同步放化疗(CCRT)、诱导化疗+放射治疗(IC)+(RT)、IC +CCRT。研究者纳入了2009-2012年间经调强放疗(IMRT)治疗的 III-IVB期鼻咽癌患者。诱导方案包括 PF(顺铂、氟尿嘧啶)和TP(多西紫杉醇、顺铂),每3周进行一次诱导治疗,持续2-3个周期;

研究者对经调强放疗(IMRT)治疗后的局部区域晚期鼻咽癌患者进行了一项研究,比较以下几种治疗方式的生存结局和急性毒性作用:同步放化疗(CCRT)、诱导化疗+放射治疗(IC)+(RT)、IC +CCRT。

研究者纳入了2009-2012年间经调强放疗(IMRT)治疗的 III-IVB期鼻咽癌患者。诱导方案包括 PF(顺铂、氟尿嘧啶)和TP(多西紫杉醇、顺铂),每3周进行一次诱导治疗,持续2-3个周期;并发方案是顺铂,也是每3周进行一次,持续2-3个周期。使用倾向得分匹配方法按1:1:1配对。

该研究共纳入147名患者,每组49名,中位数随访38.5个月(4.5-56个月)。3年无病生存率、整体生存率、无远处转移生存率、无局部区域复发存活率在CCRT组分别为82.1 %、92.8 %、87 %和90.4 %,IC+PT组分别为86.3 %、91.0 %、91.6 %和94.4 %,IC+CCRT组分别为 87.8 %、95.8 %、93.8 %和93.9 %。无论是单变量还是多变量分析,三组不同治疗方案间相关生存率未发现统计学差异。每组间3-4级急性毒性反应相似。

研究结果表明,经IMRT治疗的局部区域晚期鼻咽癌患者使用CCRT、IC+PT或IC+CCRT治疗方案具有相似疗效。但未来还需要大样本、长期随访研究以证实该结果。

原始出处:

Li WF, Li YQ,et al.Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.BMC Cancer. 2015 Oct 27;15:810.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=133836, encodeId=e91e133836ac, content=赞了!深度好文,深入学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 23 20:08:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974660, encodeId=e33619e466031, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Feb 04 01:26:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904964, encodeId=3a7a1904964ed, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Thu Jul 14 14:26:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67139, encodeId=928b6e139e6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:17:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47834, encodeId=752a4e834c5, content=中国的研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 00:56:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
    2016-09-23 ylzr123

    赞了!深度好文,深入学习。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=133836, encodeId=e91e133836ac, content=赞了!深度好文,深入学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 23 20:08:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974660, encodeId=e33619e466031, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Feb 04 01:26:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904964, encodeId=3a7a1904964ed, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Thu Jul 14 14:26:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67139, encodeId=928b6e139e6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:17:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47834, encodeId=752a4e834c5, content=中国的研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 00:56:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=133836, encodeId=e91e133836ac, content=赞了!深度好文,深入学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 23 20:08:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974660, encodeId=e33619e466031, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Feb 04 01:26:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904964, encodeId=3a7a1904964ed, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Thu Jul 14 14:26:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67139, encodeId=928b6e139e6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:17:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47834, encodeId=752a4e834c5, content=中国的研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 00:56:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=133836, encodeId=e91e133836ac, content=赞了!深度好文,深入学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 23 20:08:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974660, encodeId=e33619e466031, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Feb 04 01:26:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904964, encodeId=3a7a1904964ed, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Thu Jul 14 14:26:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67139, encodeId=928b6e139e6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:17:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47834, encodeId=752a4e834c5, content=中国的研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 00:56:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
    2016-03-04 不再犹豫

    学习啦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=133836, encodeId=e91e133836ac, content=赞了!深度好文,深入学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Sep 23 20:08:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974660, encodeId=e33619e466031, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Feb 04 01:26:00 CST 2016, time=2016-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904964, encodeId=3a7a1904964ed, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Thu Jul 14 14:26:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67139, encodeId=928b6e139e6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:17:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47834, encodeId=752a4e834c5, content=中国的研究?, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 00:56:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
    2015-12-26 jetleo

    中国的研究?

    0

相关资讯

BMC Cancer:鼻咽癌鼻窦侵犯:预后及其在AJCC分期中T分期的循证医学依据

研究背景:一个理想的分期系统除具备权威性、稳定性及先进性外,还应对临床医师和研究者同时具有实用性,易于被广泛接受使用。数十年来,基于循征医学的鼻咽癌分期系统不断发展。西方国家及香港等地区经历了从何氏分期到目前使用的UICC/AJCC分期第七版,国内则经过了从1959年的天津分期到2008分期的更新。[pdf]目前,国际上使用的鼻咽癌分期系统是UICC和美国抗癌协会(AJCC)提出的分期标准。由于鼻

IJPT:质子治疗可降低头颈癌患者对饲管的需求

来自美国德克萨斯大学MD安德森质子治疗中心的一项新研究为质子疗法提供了进一步的证据——特别是多领域优化质子治疗的强度调制(MFO-IMPT)——对于某些患者来说可能是更好的治疗方法,减小饲管给患者所带来的风险及医疗成本。据本研究作者发表于《国际粒子治疗杂志》的最新一期文章显示,每年使用饲管的直接费用超过31000美元(据估计,从2001年开始,甚至更高)。“虽然调强放射治疗有效,但是它同时也辐射了

BMC Cancer:中国广州大样本研究结果表明吸烟增加鼻咽癌死亡风险

全球鼻咽癌发病率很低,但在北非和东南亚非常高,尤其是中国广东!烟草会导致头颈部癌症,但目前没有报道称吸烟和鼻咽癌间的联系。研究者对广州的数据进行了一项前瞻性研究,探究鼻咽癌高发地区吸烟和鼻咽癌死亡率的关系。研究采集了1988年3月-1992年12月的人口统计学资料、吸烟情况等数据,以及直到1999年参与者状态和死因数据。使用Cox风险比例模型分析吸烟和鼻咽癌死亡率间联系。该研究共纳入101,823

JAMA OHNS:鼻咽癌患者头颈部放疗的影响——睡眠相关呼吸障碍?

睡眠呼吸障碍(sleep-related breathing disorders,SRBDs)是一种长期被忽视的常见病,其发病率高,在正常成人中为2%至4%,男性明显多于女性,随着人口老龄化和肥胖问题的日趋严重,SEBDs的发病率呈现逐渐上升的趋势。SRBDs的危害性极大,可引起高血压、冠心病、脑血管疾病等病死率和致残率均相当高的疾病。然而,对于鼻咽癌与睡眠相关呼吸障碍之间的关系,目前研究并不清楚

ASCO 2015:III期临床研究:康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效

背景:目前在接受放化疗治疗的鼻咽癌患者中,口腔黏膜炎发生率较高。截至目前,并没有有效的药物来预防和治疗口腔黏膜炎。康复新液是中国中草药复方制剂,它可以促进血管的生成以及黏膜的修复。本研究旨在观察康复新液对鼻咽癌患者放疗后引起的口腔黏膜炎(OM)及上消化道黏膜炎的效果。 方法:研究人员从五个多中心临床科室纳入了240例证实鳞状鼻咽癌的患者。将其随机分为对照组和治疗组。所有患者都接受根治性放化疗。治疗

Cell Death Dis:中国科学家发现抑制鼻咽癌生长转移新机制

近日,国际生物学期刊cell death &disease在线发表了来自中山大学一研究小组的最新研究成果。他们通过基因芯片分析发现miR-34c在鼻咽癌(NPC)中发生下调,并通过实验证明miR-34c能够通过直接抑制原癌基因MET表达抑制鼻咽癌肿瘤生长和转移。这项研究对治疗鼻咽癌提供了机制上的借鉴意义。 研究人员通过对NPC细胞系和病人组织样本进行分析发现,miR-34c在细胞和组织内均发生明